Ditropan and Visual acuity reduced - a phase IV clinical study of FDA data

Summary:

Visual acuity reduced is reported as a side effect among people who take Ditropan (oxybutynin chloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Gilenya, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Visual acuity reduced when taking Ditropan. It is created by eHealthMe based on reports of 11,571 people who have side effects when taking Ditropan from the FDA, and is updated regularly.

What is Ditropan?

Ditropan has active ingredients of oxybutynin chloride. It is often used in urge incontinence. eHealthMe is studying from 11,799 Ditropan users. Check the latest studies of Ditropan.

What is Visual acuity reduced?

Visual acuity reduced (reduced clearness of vision) is found to be associated with 1,494 drugs and 1,887 conditions by eHealthMe. Check the latest studies of Visual acuity reduced.

On Jul, 11, 2026

11,571 people reported to have side effects when taking Ditropan.
Among them, 56 people (0.48%) have Visual acuity reduced.

Could Ditropan cause Visual acuity reduced?

Among these 56 people:

How long have people been on Ditropan when they have Visual acuity reduced? *

What is the gender of people who have Visual acuity reduced when taking Ditropan? *

female: 74.55 %
male: 25.45 %

What is the age of people who have Visual acuity reduced when taking Ditropan? *

What are other drugs people take besides Ditropan? *

What are other side effects people have besides Visual acuity reduced? *

Fatigue (feeling of tiredness): 16 people, 28.57%
Vision Blurred: 15 people, 26.79%
Lymphocyte Count Decreased: 12 people, 21.43%
Movement - Uncoordinated: 10 people, 17.86%
Gait Disturbance: 10 people, 17.86%
Tremor (trembling or shaking movements in one or more parts of your body): 10 people, 17.86%
Speech Impairment (Adult) (inability to speak (adult)): 9 people, 16.07%
Hypoaesthesia (reduced sense of touch or sensation): 8 people, 14.29%
Diplopia (double vision): 8 people, 14.29%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 7 people, 12.50%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 20 people, 35.71%
Pain: 8 people, 14.29%
Iron Deficiency Anaemia: 6 people, 10.71%
Progressive Multiple Sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord): 3 people, 5.36%
Stress And Anxiety: 3 people, 5.36%
Sinusitis (inflammation of sinus): 3 people, 5.36%
Depression: 3 people, 5.36%
Osteoporosis (bones weak and more likely to break): 3 people, 5.36%
Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 3 people, 5.36%
Insomnia (sleeplessness): 2 people, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Ditropan and have Visual acuity reduced?

- Check whether Visual acuity reduced is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ditropan:

Ditropan (11,799 reports)

Browse all side effects of Ditropan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Visual acuity reduced:

Visual acuity reduced (1,494 drugs)

Browse all the conditions that are associated with Visual acuity reduced:

Visual acuity reduced (1,887 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on oxybutynin chloride (the active ingredients of Ditropan) and Ditropan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.